Literature DB >> 26428317

Comprehensive screening of alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.

Jau-Yu Liau1,2, Jen-Chieh Lee1,2, Jia-Huei Tsai1,2, Ching-Yao Yang3, Tsung-Lin Liu1,2, Zhi-Long Ke1,2, Hung-Han Hsu1,2, Yung-Ming Jeng1,2.   

Abstract

According to cytogenetic aberrations, sarcomas can be categorized as complex or simple karyotype tumors. Alternative lengthening of telomeres is a telomere-maintenance mechanism common in sarcomas. Recently, this mechanism was found to be associated with loss of either α-thalassemia/mental retardation syndrome X-linked (ATRX) or death domain-associated (DAXX) protein. We previously reported that alternative lengthening of telomeres and loss of ATRX expression were common in leiomyosarcoma, angiosarcoma, pleomorphic liposarcoma, and dedifferentiated liposarcoma. In the present study, we screened an additional 245 sarcomas of other types to determine the prevalence of alternative lengthening of telomeres, loss of ATRX/DAXX expression, and their relationship. Undifferentiated pleomorphic sarcomas were frequently alternative lengthening of telomeres positive (65%) and loss of ATRX was seen in approximately half of the alternative lengthening of telomeres-positive tumors. Nineteen of 25 myxofibrosarcomas were alternative lengthening of telomeres-positive, but only one was ATRX deficient. Three of 15 radiation-associated sarcomas were alternative lengthening of telomeres positive, but none of them was ATRX deficient. Alternative lengthening of telomeres and/or loss of ATRX were uncommon in malignant peripheral nerve sheath tumors, gastrointestinal stromal tumors, and embryonal rhabdomyosarcomas. By contrast, none of the 71 gene fusion-associated sarcomas was ATRX deficient or alternative lengthening of telomeres positive. All tumors exhibited preserved DAXX expression. Combining our previous studies and this study, a total of 384 sarcomas with complex karyotypes were examined, 83 of which were ATRX deficient (22%). By telomere-specific fluorescence in situ hybridization, 45% (138/308) were alternative lengthening of telomeres positive, 55% (76/138) of which were ATRX deficient. Loss of ATRX was highly associated with alternative lengthening of telomeres (P<0.001). We conclude that alternative lengthening of telomeres is a frequent telomere-maintenance mechanism in cytogenetically complex sarcomas. Loss of ATRX is highly associated with this feature.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26428317     DOI: 10.1038/modpathol.2015.114

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  38 in total

Review 1.  Telomere length maintenance--an ALTernative mechanism.

Authors:  N J Royle; J Foxon; J N Jeyapalan; A Mendez-Bermudez; C L Novo; J Williams; V E Cotton
Journal:  Cytogenet Genome Res       Date:  2009-01-30       Impact factor: 1.636

Review 2.  The role of telomeres in stem cells and cancer.

Authors:  Cagatay Günes; K Lenhard Rudolph
Journal:  Cell       Date:  2013-01-31       Impact factor: 41.582

Review 3.  Alternative lengthening of telomeres: models, mechanisms and implications.

Authors:  Anthony J Cesare; Roger R Reddel
Journal:  Nat Rev Genet       Date:  2010-03-30       Impact factor: 53.242

4.  Telomere maintenance mechanisms in liposarcomas: association with histologic subtypes and disease progression.

Authors:  Aurora Costa; Maria Grazia Daidone; Laura Daprai; Raffaella Villa; Sabrina Cantù; Silvana Pilotti; Luigi Mariani; Alessandro Gronchi; Jeremy D Henson; Roger R Reddel; Nadia Zaffaroni
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

5.  Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.

Authors:  Rachel Litman Flynn; Kelli E Cox; Maya Jeitany; Hiroaki Wakimoto; Alysia R Bryll; Neil J Ganem; Francesca Bersani; Jose R Pineda; Mario L Suvà; Cyril H Benes; Daniel A Haber; Francois D Boussin; Lee Zou
Journal:  Science       Date:  2015-01-16       Impact factor: 47.728

6.  SMARCB1/INI1 tumor suppressor gene is frequently inactivated in epithelioid sarcomas.

Authors:  Piergiorgio Modena; Elena Lualdi; Federica Facchinetti; Lisa Galli; Manuel R Teixeira; Silvana Pilotti; Gabriella Sozzi
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

7.  Telomerase activity in gastrointestinal stromal tumors.

Authors:  S Sakurai; M Fukayama; Y Kaizaki; K Saito; K Kanazawa; M Kitamura; Y Iwasaki; T Hishima; Y Hayashi; M Koike
Journal:  Cancer       Date:  1998-11-15       Impact factor: 6.860

8.  Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  Stephen Qualman; James Lynch; Julia Bridge; David Parham; Lisa Teot; William Meyer; Alberto Pappo
Journal:  Cancer       Date:  2008-12-01       Impact factor: 6.860

9.  Distinct factors control histone variant H3.3 localization at specific genomic regions.

Authors:  Aaron D Goldberg; Laura A Banaszynski; Kyung-Min Noh; Peter W Lewis; Simon J Elsaesser; Sonja Stadler; Scott Dewell; Martin Law; Xingyi Guo; Xuan Li; Duancheng Wen; Ariane Chapgier; Russell C DeKelver; Jeffrey C Miller; Ya-Li Lee; Elizabeth A Boydston; Michael C Holmes; Philip D Gregory; John M Greally; Shahin Rafii; Chingwen Yang; Peter J Scambler; David Garrick; Richard J Gibbons; Douglas R Higgs; Ileana M Cristea; Fyodor D Urnov; Deyou Zheng; C David Allis
Journal:  Cell       Date:  2010-03-05       Impact factor: 41.582

10.  Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.

Authors:  Lauren Fishbein; Sanika Khare; Bradley Wubbenhorst; Daniel DeSloover; Kurt D'Andrea; Shana Merrill; Nam Woo Cho; Roger A Greenberg; Tobias Else; Kathleen Montone; Virginia LiVolsi; Douglas Fraker; Robert Daber; Debbie L Cohen; Katherine L Nathanson
Journal:  Nat Commun       Date:  2015-01-21       Impact factor: 14.919

View more
  26 in total

1.  Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model.

Authors:  Elizabeth G Demicco; Michael J Wagner; Robert G Maki; Vishal Gupta; Ilya Iofin; Alexander J Lazar; Wei-Lien Wang
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

Review 2.  Solid tumours hijack the histone variant network.

Authors:  Flávia G Ghiraldini; Dan Filipescu; Emily Bernstein
Journal:  Nat Rev Cancer       Date:  2021-02-10       Impact factor: 60.716

Review 3.  Alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.

Authors:  Xiaolei Ren; Chao Tu; Zhenchu Tang; Ruofei Ma; Zhihong Li
Journal:  Oncol Lett       Date:  2018-03-22       Impact factor: 2.967

4.  miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells.

Authors:  Graziella Cimino-Reale; Paolo Gandellini; Francesca Santambrogio; Marta Recagni; Nadia Zaffaroni; Marco Folini
Journal:  J Hematol Oncol       Date:  2017-07-17       Impact factor: 17.388

5.  Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases.

Authors:  Christian Koelsche; Daniel Schrimpf; Andreas von Deimling; Gunhild Mechtersheimer; Lars Tharun; Eva Roth; Dominik Sturm; David T W Jones; Eva-Kristin Renker; Martin Sill; Annika Baude; Felix Sahm; David Capper; Melanie Bewerunge-Hudler; Wolfgang Hartmann; Andreas E Kulozik; Iver Petersen; Uta Flucke; Hendrik W B Schreuder; Reinhard Büttner; Marc-André Weber; Peter Schirmacher; Christoph Plass; Stefan M Pfister
Journal:  Clin Sarcoma Res       Date:  2017-05-04

Review 6.  Telomere maintenance in soft tissue sarcomas.

Authors:  Nicholas Eastley; Barbara Ottolini; Carmen Garrido; Jacqueline A Shaw; Thomas Alasdair McCulloch; Robert U Ashford; Nicola J Royle
Journal:  J Clin Pathol       Date:  2017-02-09       Impact factor: 3.411

Review 7.  Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).

Authors:  Marco De Vitis; Francesco Berardinelli; Antonella Sgura
Journal:  Int J Mol Sci       Date:  2018-02-18       Impact factor: 5.923

8.  Case Report: Triple Primary Malignant Tumors of the Esophagus, Stomach, and Colon in a Patient With Genetic Analysis.

Authors:  Xiaoli Zhan; Lingzhe He; Kai Song; Shuliang Cao; Erhong Meng; Yuedong Wang
Journal:  Front Genet       Date:  2021-07-09       Impact factor: 4.599

Review 9.  The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) Phenotype.

Authors:  João P Amorim; Gustavo Santos; João Vinagre; Paula Soares
Journal:  Genes (Basel)       Date:  2016-09-19       Impact factor: 4.096

10.  Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.

Authors: 
Journal:  Cell       Date:  2017-11-02       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.